Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of PKN605 in Participants With Renal Impairment
NCT07797322Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Primary completion
- Feb 2027
01
Overview
Phase 1, open-label trial of PKN605 (3 arms), sponsored by Novartis. Primary endpoints: Maximum Observed Plasma Concentration up to 5 days, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration up to 5 days and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PKN605
Beyond the preview
Go deeper on NCT07797322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797322.